Close Menu

NEW YORK (GenomeWeb) – Targeted sequencing matched mutations to therapeutic options in more than half of the non-small cell lung cancer patients analyzed in a new study.

NSCLC accounts for 85 percent to 90 percent of the approximately 222,500 new lung cancer cases in the US each year. Recent studies have uncovered a number of genes that are frequently mutated in NSCLC and guidelines from the National Comprehensive Cancer Network (NCCN) recommend testing for seven genes in NSCLC patients to match them to targeted therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.